CME Presentations

Multiple Myeloma



  • Attaya Suvannasankha, MD

    Attaya Suvannasankha, MD

    Attaya Suvannasankha, MD

    Associate Professor, Clinical Medicine

    Attaya Suvannasankha, MD is a hematologist-oncologist and associate professor of clinical medicine at Indiana University School of Medicine, as well as a physician-scientist at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Nationally recognized as an expert for moving research from the bench to the bedside, she serves as co-chair of the myeloma working group of the Big Ten Cancer Research Consortium. Since her appointment at Indiana University in 2003, Dr. Suvannasankha has worked to develop an interdisciplinary team of clinicians and researchers to bring the best care to patients with multiple myeloma (MM) through translational research. She has led multiple trials of new agents and combinations with a focus on novel immunotherapy.
  • Hans Lee, MD

    Hans Lee, MD

    Hans Lee, MD

    Associate Professor, Department of Lymphoma/Myeloma

    Hans Lee, MD is an associate professor and director of multiple myeloma (MM) clinical research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. His clinical and research efforts are focused on advancing the care and treatment of patients with MM. Dr. Lee’s primary research goals are directed toward developing novel approaches to treat MM through early phase investigator-initiated and industry-sponsored clinical trials with a strong translational emphasis to interrogate myeloma pathobiology and mechanisms of drug response and resistance.

CME Information

Global Logo PQH Logo

Placing Bispecific Antibodies in the Treatment Landscape for Heavily Pretreated Multiple Myeloma

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


This activity was released on September 21st, 2023 and is valid until September 21st, 2024. Requests for credit must be made no later than September 21, 2024.


The educational design of this activity addresses the needs of – Hematologic oncologists, hematologists, medical oncologists, pathologists, and specialty advanced practice providers (NPs and PAs)


Decades of progress and several landmark advancements have led to today’s standard-of-care frontline therapies for multiple myeloma (MM), which consist of immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies. However, efficacy is not durable, with the majority of patients eventually relapsing due to induced drug resistance or emergence of genetically heterogeneous subclones. To explore both current and emerging treatment options for MM, join a panel of expert hematologists and oncologists to discuss new clinical data on treatments, their differences and mechanisms of action, and how to anticipate and manage side effects. Panelists will also explore patient and caregiver preferences, the shared decision-making process, and strategies to resolve disparities in treatment priorities.


After completing this activity, the participant should be better able to:
  • Describe the rationale behind the development of new therapies for RRMM
  • Evaluate clinical data related to new MOAs, such as bispecific antibodies in development for RRMM
  • Discuss the role of patient and caregiver preferences in the shared decision-making process and how to align treatment priorities



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Conflicts of Interest
Attaya Suvannasankha, MD
Associate Professor of Clinical Medicine
Indiana University School of Medicine
Consultant, Advisor, Speaker: Janssen Oncology, GlaxoSmithKline
Researcher: Janssen Oncology, Sutro, Regeneron, Genentech, Karyopharm
Hans Lee, MD
Associate Professor
Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Consultant, Advisor, Speaker: Takeda, Allogene Therapeutics, Bristol Myers Squibb, Genentech, Regeneron, GlaxoSmithKline, Janssen, Sanofi, Monte Rosa Therapeutics
Researcher: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Takeda

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at